Yoshimi Fujishima
Kobe, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Early LMR Dynamics and AFP Status in Advanced HCC Treated With Atezolizumab/Bevacizumab.
Journal: Anticancer research
Published: May 23, 2026
Impact of intrahepatic lesions on lesion-specific response rates in patients with hepatocellular carcinoma treated with lenvatinib or immune checkpoint inhibitors.
Journal: HPB : the official journal of the International Hepato Pancreato Biliary Association
Published: August 27, 2025
Impact of Borderline Resectable Criteria on Hepatocellular Carcinoma Treatment From the Perspective of Tumor Burden.
Journal: World journal of surgery
Published: August 07, 2025
Prognosis of Hepatectomy versus Systemic Chemotherapy Based on Oncological Resectability Criteria for Borderline Resectable Hepatocellular Carcinoma.
Journal: Liver cancer
Published: March 07, 2025
Multidisciplinary strategies including local treatment to achieve drug-free status after atezolizumab plus bevacizumab treatment in hepatocellular carcinoma.
Journal: Oncology letters
Published: February 25, 2025
Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Journal: Anticancer research
Published: November 15, 2024
The potential efficacy of atezolizumab plus bevacizumab treatment for hepatocellular carcinoma patients with macroscopic portal vein tumor thrombus.
Journal: Surgery today
Published: September 30, 2024
Current Roles of Ramucirumab in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
Journal: Anticancer research
Published: January 23, 2024
Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: September 20, 2023
Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
Journal: Anticancer research
Published: January 14, 2022
Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report.
Journal: BMC gastroenterology
Published: August 21, 2021
Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer.
Journal: Internal medicine (Tokyo, Japan)
Published: May 17, 2021
Last Updated: 09/26/2026